Therapeutic Solutions International

OverviewSuggest Edit

Therapeutic Solutions International focuses on immune modulation for the treatment of various diseases. The Company develops a range of immune-modulatory agents to target various cancers, enhance maternal and fetal health, and fight periodontal disease, as well as for daily health. Its flagship product is ProJuvenol, a synergistic blend of anti-aging ingredients based upon pterostilbene to promote cellular rejuvenation and healthy functionality.
TypePublic
Founded2007
HQOceanside, US
Websitetherapeuticsolutionsint.com

Latest Updates

Employees (est.) (Feb 2019)3(-57%)
Revenue (FY, 2018)$3.5 K(+23%)
Share Price (Oct 2017)$0 (-25%)

Therapeutic Solutions International Office Locations

Therapeutic Solutions International has an office in Oceanside
Oceanside, US (HQ)
4093 Oceanside Blvd
Show all (1)

Therapeutic Solutions International Financials and Metrics

Therapeutic Solutions International Revenue

Therapeutic Solutions International's revenue was reported to be $3.48 k in FY, 2018
USD

Revenue (Q3, 2019)

11.3k

Net income (Q3, 2019)

(446.2k)

EBIT (Q3, 2019)

(199.6k)

Market capitalization (31-Oct-2017)

5.5m

Closing stock price (31-Oct-2017)

0.0

Cash (30-Sept-2019)

20.0k

EV

6.4m
Therapeutic Solutions International's current market capitalization is $5.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

1.7m1.8m311.6k1.9k5.0k2.9k3.5k

Cost of goods sold

59.9k80.1k11.8k3.2k1.6k823.0

Gross profit

1.6m1.8m299.8k(1.3k)3.4k2.0k

Gross profit Margin, %

96%96%96%(67%)68%71%
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

607.8k454.9k404.8k420.0325.0530.0735.01.3k548.0745.0630.0600.01.0k3.3k2.5k8.9k11.3k

Cost of goods sold

17.3k15.4k13.9k13.8k13.3k3.6k2.9k3.2k1.9k97.0166.0140.0215.0394.0198.0227.0191.0105.0104.0

Gross profit

593.9k441.1k391.6k(3.6k)(2.9k)(3.2k)323.0159.0390.0520.0927.0350.0518.0439.0495.0915.0

Gross profit Margin, %

98%97%97%77%49%74%71%70%64%70%70%83%90%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

88.0k35.0k12.5k2.9k2.2k21.9k29.022.4k

Accounts Receivable

37.4k16.4k2.2k

Prepaid Expenses

490.0k14.5k68.6k139.0k213.4k14.3k

Inventories

48.2k30.8k26.8k29.7k36.4k1.5k
Quarterly
USDY, 2019

EV/EBIT

-32.1 x

EV/CFO

-24.9 x

Financial Leverage

-0.2 x
Show all financial metrics

Therapeutic Solutions International Online and Social Media Presence

Embed Graph

Therapeutic Solutions International News and Updates

Therapeutic Solutions International Continues to Expand Chronic Traumatic Encephalopathy Intellectual Property Portfolio

Patent filed for Autologous Neurogenic Cells in Professional Athletes at Risk of CTE Patent filed for Autologous Neurogenic Cells in Professional Athletes at Risk of CTE

Therapeutic Solutions International CEO Issues Shareholder Letter

OCEANSIDE, Calif., Dec. 31, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) addresses shareholders in letter form.

Therapeutic Solutions International Completes Phase 1 Clinical Trial in Advanced Cancer Patients for Right to Try Access of its StemVacs Product for American Cancer Patients

Company to use Phase I Data of its Cancer Stem Cell Immunotherapy to Allow for use in the USA under President Donald Trump's  Right to Try Law

Therapeutic Solutions International Reports Synergistic Enhancement of Ozone Therapy Efficacy in Prostate, Breast and Ovarian Cancer Cells by Pterostilbene

Clinical Stage Cancer Immunotherapy Biotechnology Company Files Patent Expanding Uses of its Pterostilbene Based Product Pipeline

Therapeutic Solutions International Frequently Asked Questions

  • When was Therapeutic Solutions International founded?

    Therapeutic Solutions International was founded in 2007.

  • How many employees does Therapeutic Solutions International have?

    Therapeutic Solutions International has 3 employees.

  • What is Therapeutic Solutions International revenue?

    Latest Therapeutic Solutions International annual revenue is $3.5 k.

  • What is Therapeutic Solutions International revenue per employee?

    Latest Therapeutic Solutions International revenue per employee is $1.2 k.

  • Who are Therapeutic Solutions International competitors?

    Competitors of Therapeutic Solutions International include KinDex Pharmaceuticals, ADC Therapeutics and Valneva.

  • Where is Therapeutic Solutions International headquarters?

    Therapeutic Solutions International headquarters is located at 4093 Oceanside Blvd, Oceanside.

  • Where are Therapeutic Solutions International offices?

    Therapeutic Solutions International has an office in Oceanside.

  • How many offices does Therapeutic Solutions International have?

    Therapeutic Solutions International has 1 office.